Goldman Sachs Starts Coverage on Biohaven with Buy Rating
Goldman Sachs initiates coverage on Biohaven with a Buy rating and $23 price target, highlighting BHV-1400 and its potential in the large IgA nephropathy market.
Goldman Sachs initiates coverage on Biohaven with a Buy rating and $23 price target, highlighting BHV-1400 and its potential in the large IgA nephropathy market.
RBC Capital upgrades Biohaven to Outperform, raises price target to $22, and highlights improving data, lower risk, and strong 2026 catalysts.
Bank of America upgrades Biohaven's price target by 50% following positive pipeline updates, but maintains neutral rating citing uncertain 2026 catalysts.
Biohaven's (BHVN) experimental depression treatment BHV-7000 didn't meet its primary goal in Phase 2 testing, though some patient subgroups showed promising trends.
Biohaven's (BHVN) BHV-1510 cancer drug shows impressive response rates in lung, endometrial, and bladder cancers with fewer side effects than similar treatments.
UBS cuts Biohaven to Neutral from Buy, lowering the price target to $11 due to multiple R&D and regulatory setbacks and rising competition in its Kv7 program.